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Abstract
Objectives—The eVect of interferon-â1a
(INF-â1a; Rebif®) was studied in patients
with chronic motor neuropathies not
improving after conventional treatments
such as immunoglobulins, steroids, cyclo-
phosphamide or plasma exchange.
Methods—A prospective open study was
performed with a duration of 6–12 months.
Three patients with a multifocal motor
neuropathy and one patient with a pure
motor form of chronic inflammatory de-
myelinating polyneuropathy were en-
rolled. Three patients had anti-GM1
antibodies. Treatment consisted of sub-
cutaneous injections of IBF-â1a (6 MIU),
three times a week. Primary outcome was
assessed at the level of disability using the
nine hole peg test, the 10 metres walking
test, and the modified Rankin scale. Sec-
ondary outcome was measured at the
impairment level using a slightly modified
MRC sumscore.
Results—All patients showed a significant
improvement on the modified MRC sum-
score. The time required to walk 10 metres
and to fulfil the nine hole peg test was also
significantly reduced in the first 3 months
in most patients. However, the translation
of these results to functional improvement
on the modified Rankin was only seen in
two patients. There were no severe ad-
verse events. Motor conduction blocks
were partially restored in one patient only.
Anti-GM1 antibody titres did not change.
Conclusion—These findings indicate that
severely aVected patients with chronic
motor neuropathies not responding to
conventional therapies may improve when
treated with INF-â1a. From this study it is
suggested that INF-â1a should be admin-
istered in patients with chronic motor
neuropathies for a period of up to 3
months before deciding to cease treat-
ment. A controlled trial is necessary to
confirm these findings.
(J Neurol Neurosurg Psychiatry 1999;66:197–201)
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Multifocal motor neuropathy is a chronic
immune mediated demyelinating neuropathy.1 2
Patients with multifocal motor neuropathy
mostly have a stepwise progression of asymmet-
ric muscle weakness and amyotrophy localised
in the anatomical distribution areas of peripheral
nerves. Sensory symptoms are generally not
present. The electrophysiological hallmark of
multifocal motor neuropathy is persistent con-
duction block. Most patients with this disease
have high titre antibodies against the ganglioside
GM1.1 2 Clinically, multifocal motor neuropathy
is also described as an asymmetric pure motor
variant of chronic inflammatory demyelinating
polyneuropathy with multifocal motor conduc-
tion blocks. Especially, during the evolution of
multifocal motor neuropathy the multifocal
character may gradually evolve in a more or less
symmetric pattern, clinically resembling the
motor form of chronic inflammatory demyeli-
nating polyneuropathy. Pathological studies
have also linked multifocal motor neuropathy
with chronic inflammatory demyelinating
polyneuropathy.3 4
The first line of treatment of patients with
multifocal motor neuropathy constitutes high
dosage of intravenous immunoglobulins
(IVIg).5 6 Initial reports suggested benefit from
treatment with cyclophosphamide.1 7 However,
not all patients improve after these treatments.
In the group of non-responders at least, there is
a need for new treatment modalities. Such a
new treatment might be interferon-â1a (IFN-
â1a).
The main objective of this study was to
investigate whether treatment with IFN-â1a
resulted firstly in improvement at the level of
disability and secondly at the impairment level
in severely aVected patients with chronic motor
neuropathies not improving after conventional
therapies such as IVIg, cyclophosphamide,
steroids, or plasma exchange. Additionally, the
influence of IFN-â1a on neurophysiological
findings and anti-GM1 antibody titres was
investigated.
Patients and methods
PATIENTS’ CHARACTERISTICS (TABLE) AND
THERAPY
Four patients entered this prospective open
study. Three patients were diagnosed as having
multifocal motor neuropathy based on the
clinical and electrophysiological characteristics
for multifocal motor neuropathy.2 The fourth
patient had a chronic symmetric pure motor
neuropathy with rapidly evolving symptoms at
onset in the lower limbs. This patient met the
clinical, electrophysiological, and CSF criteria
for the diagnosis of chronic inflammatory
demyelinating polyneuropathy.8 Immunofixa-
tion in this patient, however, showed an IgM-ë
and an IgG-ê monoclonal gammopathy. Ex-
tended haematological investigation showed no
other abnormalities.
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Two patients with multifocal motor neu-
ropathy and the patient with chronic inflamma-
tory demyelinating polyneuropathy had IgM
anti-GM1 antibodies. Anti-MAG (myelin asso-
ciated glycoprotein) antibodies were absent in
the patient with chronic inflammatory demyeli-
nating polyneuropathy. The duration of the
symptoms ranged from 7 to 9 years before the
start of INF-â1a treatment. All patients devel-
oped marked amyotrophy and their ambulation
also decreased gradually during the disease
period. At entry to this study, one patient was
almost always wheelchair dependent and two
patients needed a walking stick and ankle
orthesis at both sites to cover short distances
and a wheelchair for longer distances. Patient 3
did not experience much problem when walk-
ing very short distances, but she noticed that
her legs gave way after walking for 5–10
minutes. Her walking endurance was also dete-
riorating and she could walk outdoors for only
15 minutes. The patients received diVerent
types of therapy during the course of their
illness, but despite these treatments none
showed clinical improvement. The study was
approved by the medical ethics committee of
our hospital and took place between February
1996 and September 1997. All patients gave
informed consent. No immunosuppressive
drugs were given within the 3 months before
the study.
IFN-â1a (Rebif®; Serono Benelux) was self
administered at a dosage of 6 million IU three
times a week for 6 months and then, if clinical
improvement was found (defined as at least one
point improvement on the modified Rankin
scale) the treatment was continued for an addi-
tional period of 6 months. To minimise the
chance of adverse events a lower dose of 1.2
MIU Rebif was administered during the first
week and 3.0 MIU during the second week.
Thereafter the full dosage was given. Acetami-
nophen (500–1000 mg/day) was administered
prophylactically during the first 6 weeks of
treatment to ameliorate known constitutional
symptoms of IFN-â1a.
CLINICAL ASSESSMENT
Primary outcome was assessed at the disability
level using the nine hole peg test, the 10 metres
walking test, and the modified Rankin scale.9–11
All patients received training in fulfilling the
nine hole peg test before the start of the study
to exclude any training eVect. Secondary
outcome was measured at the impairment level
using the MRC sumscore, which was slightly
modified.12 The following muscle pairs were
examined: upper arm abductors, elbow flexors,
wrist extensors, interosseus muscles, hip flex-
ors, knee extensors, foot plantar flexors, and
foot dorsal flexors (score range 0–80). All tests
were assessed under predefined standard con-
ditions. The scales were applied at entry and
once a week in weeks 2, 4, 6, 8, 10, 12, 16, 21,
and 26 in all patients, 3 months after stopping
IFN-â1a in two patients and in weeks 32,42,
and 52 in the other two patients. Two
investigators (ISJM/PAvD) did the follow up
assessments, each examining two patients. All
measurements were compared with the base-
line findings for each patient. Adverse events
were recorded.
ADDITIONAL INVESTIGATIONS
Routine physical examination and laboratory
studies, including enzyme linked immunosorb-
ent assay (ELISA) tests for antibodies against
the ganglioside GM113 were performed within
2 weeks before the start of the study and
subsequently five times during the treatment
period. Electromyography was performed
under standard conditions using supramaximal
stimulation by the same examiner (JM) within
2 weeks before day 1, and consecutively 3–5
times during therapy time. Nerve conduction
velocities and compound muscle action poten-
tials (CMAPs) were examined in eight motor
nerves (four of the upper and four of the lower
limbs). The examination always included the
aVected nerve(s) resulting in impairment.
STATISTICAL ANALYSIS
Conventional linear and linear spline (piecewise
method) regression analyses14 were used to
evaluate the obtained serial data for the nine
hole peg test and the 10 metres walking test.
The knots of the linear spline functions were
taken at week 12 of treatment, based on the
clinical picture found. All analyses were per-
formed using Stata 5.0 for Windows 95 (Stata
Statistical Software: Release 5.0. 702 University
Drive East, College station, TX: Stata Corpora-
tion 1997). A p value<0.05 was considered to
be significant.
Clinical data before onset of treatment with interferon-â1a (Rebif)
Patient Age/ sex Diagnosis
Onset of
symptoms
Initially aVected
motor nerves
Duration of
illness(y) Previous treatments
Anti-GM1
antibodies
1 39/M MMN UL/D/A L Radial/L Ulnar 9 IVIg1/Cyclophos (2x)2a/Predn3 +
R Radial Cyclophos2b+Predn3/
IVIg1+Mpredn4
(1 : 12800)
2 60/F MMN UL/D/A R Median/L
Ulnar
8 IVIg (3x)1 −
3 53/F MMN UL/D/A L Ulnar 7 IVIg (2x)1/IVIg1+Mpredn4 +
(1 : 200)
4 54/M CIDP LL/D>P/S L+R Posterior
tibial and
peroneal
9 IVIg (2x)1/IVIg1+Mpredn4/
Predn3/PE5
Cyclophos2a+Predn3/Cyclophos2c
+
(1 : 12800)
MMN=multifocal motor neuropathy; CIDP=chronic inflammatory demyelinating polyneuropathy; UL=upper limb; LL=lower
limb; D=distal; P=proximal; A=asymmetric; S=symmetric; L=left; R=right; IVIg=intravenous immunoglobulins;
Cyclophos=cyclophosphamide; MPredn=methylprednisolone; PE=plasma exchange; 1=0.4 g/kg body weight/day for 5 days; 2a=0.5
g/day intravenously for 14 days; 2b=0.15 g/day orally for half a year; 2c=monthly 0.5 g/day orally for 4 days for 6 months; 3=60–80
mg/day orally for 6 weeks, thereafter tapering to zero in 6 months; 4=0.5g /day for 5 days; 5=2 exchange sessions (each 2.5 litres
plasma)/week for 5 consecutive weeks.
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Results
After 2–4 weeks of treatment the patients
reported some improvement in walking and
their daily manual skills. A maximum improve-
ment was reached around 3 months of therapy,
followed by stabilisation or only minimal clini-
cal improvement. None of the patients experi-
enced deterioration during treatment.
Manual skills such as washing and brushing
hair, dressing the upper part of the body, doing
up and undoing buttons and zips, and opening
a jar or a bottle were more easily accomplished.
The time needed to fulfil the nine hole peg test
by the most aVected hand of each patient was
significantly reduced in all patients during the
first 12 weeks of treatment (fig 1). Improve-
ment was also seen in the less aVected hands in
the first 12 weeks, but this was significant only
in patient 3 (p=0.003).
Improvement in ambulation consisted of an
easier walking pattern in all patients. All
patients claimed to need less assistance from
another person and used their aid(s) less then
they were used to. An ability to walk for a
longer time was also experienced by two
patients. The time required to walk 10 metres
was significantly reduced in three patients in
the first 3 months (fig 2). Although improve-
ment in ambulation in patient 3 was not
significant, her endurance improved consider-
ably within the first 3 months of treatment as
she could walk for more than 2 hours in the
woods. The Rankin score also changed notably
in this patient, from 3 to 1 around 3 months of
therapy. Although the other three patients
showed improvement at the level of impair-
ment and disability, the Rankin score only
improved in patient 2 (from 4 to 3). The
Rankin score of the other two patients
remained 3. Based on these results we decided
to discontinue IFN-â1a in patients 1 and 4
with unchanged Rankin score after 6 months.
Patient 4 remained stable at all levels of meas-
uring outcome during the next 3 months.
Patient 1 experienced slight deterioration in
strength, dexterity, and mobility, but his
Rankin score remained unchanged. The IFN-
â1a treatment was continued for another 6
months in two patients (1and 4).
Conventional linear regression analysis
showed significant improvement in muscle
strength in all patients during the course of
treatment (p <0.001 for patients 1–3; p=0.04
for patient 4). The MRC sumscore increased
from 40 to 53, 53 to 60, 69 to 73, and 49 to 57
respectively in patients 1 to 4.
All patients had motor conduction blocks
(MCBs), outside the usual nerve compression
sites in various nerves, ranging from 35%-94%.
Only the patient with chronic inflammatory
demyelinating polyneuropathy had a marked
partial decrease in motor conduction block, in
the right ulnar (82%→37%), left ulnar
(70%→24%), and left median nerves
(94%→53%). Motor nerve conduction veloci-
ties did not improve. Anti-GM1 antibody titres
did not change. The recorded side eVects of
IFN-â1a were flu-like symptoms, fever, sweat-
ing, and erythema at the injection sites. These
disappeared gradually within 2 months. The
Figure 1 Nine hole peg test; the most aVected hand of each patient. The analysis was performed using linear spline
regression methods with the knots of the linear spline functions taken at 12 weeks.
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drug was well tolerated. Physical examination
and routine blood and urine analysis remained
normal.
Discussion
In this open prospective study, treatment with
IFN-â1a induced clinical improvement in the
first 3 months of therapy in all 4 patients with
severe chronic motor neuropathies not improv-
ing after conventional therapies. All patients
remained stable during the follow up treatment
period. However, improvement on the modi-
fied Rankin scale was only found in two
patients. A possible explanation for this is that
the grading definitions of the modified Rankin
scale are very broad classifications of disability
and therefore not sensitive enough to detect the
improvement found on the other scales used. A
similar finding was noted in a recent publi-
cation studying the eVect of IVIg in chronic
inflammatory demyelinating polyneuropathy.15
Patient 3 seemed to be less profoundly affected
than the other patients. She especially had less
severe amyotrophy, which probably explains
her better score on the modified Rankin scale.
The response to treatment, therefore, seems to
be correlated with the degree of being aVected
and the severity of amyotrophy.
Improvement after IFN-â1a was also re-
cently found by Choudhary et al in a patient
with an 8 year history of a relapsing and remit-
ting sensory-motor chronic inflammatory de-
myelinating polyneuropathy not responding to
various conventional treatments.16 This patient
received 3 MIU IFN-â1a, three times a week.
Improvement began 2 weeks after administra-
tion and as in our patients a maximum was
reached after 12 weeks. Other reports have also
shown a possible therapeutic eVect of this
group of regulatory cytokines in chronic
immune mediated neuropathies.17–19 The
present study provides some support for the
eVectiveness of IFN-â1a in patients with
chronic immune mediated neuropathies, par-
ticularly in patients with multifocal motor neu-
ropathy.
A poor correlation between clinical improve-
ment and neurophysiological data, as seen in
this study, has also been reported by others.5 6 20
One of the possible explanations for this
discrepancy is fluctuation in temporal disper-
sion, which may result in alterations of the form
of the CMAPs.20 Another possible cause is that
restored conduction blocks located at the most
proximal nerve segments may not be detected
by neurophysiological studies.
The pathophysiological mechanism of action
of IFN-â in chronic immune mediated neu-
ropathies in not known. Presently, the knowl-
edge regarding its immunoloigcal eVects is
mainly derived from studies on multiple
sclerosis.21 22 The IFN-â may counteract the
eVects of IFN-ã such as down regulation of
major histocompatibility (MHC) class II anti-
gen expression on neuroendothelial cells.21 22
This may be of importance as upregulation of
MHC class II molecules on endoneurial cells
has been shown in chronic inflammatory
demyelinating polyneuropathy.23 Other immu-
nomodulating eVects of IFN-â that may be sig-
Figure 2 10 metre walking test; analysis performed using linear spline regression methods with the knots of the linear
spline functions taken at 12 weeks.
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nificant in multifocal motor neuropathy and
chronic inflammatory demyelinating polyneu-
ropathy include enhancement of T suppressor
cell function, reduction of T cell activation and
the production of IFN-ã, down regulation of
the production of certain cytokines such as
tumour necrosis factor á and induction of the
production and secretion of interleukin-4 and
interleukin-10.21 22 24
No severe adverse events were recorded and
none of the patients deteriorated during the
administration of IFN-â1a. This suggests that
IFN-â1a can be prescribed safely in patients
with a chronic motor neuropathy. It is sug-
gested that if patients respond to treatment
with IFN-â1a, improvement generally starts
after 2 to 4 weeks. If there is no improvement
after about 3 months, therapy should be
discontinued.
In conclusion, our findings indicate that
severely aVected patients with chronic immune
mediated motor neuropathies not responding
to conventional treatments may show improve-
ment when treated with IFN-â1a. A controlled
trial is required to confirm these findings.
We thank Serono Benelux for supplying INF-â1a (Rebif). We
also thank Ms L Loman for her support in coordinating this
study.
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